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Summary
Background and objectives: The incidence of deﬁnite stent thrombosis (ST) after
use of drug-eluting stents (DES), as deﬁned by the Academic Research Consortium,
is known to be lower in Japan than in western countries. However, a statistical dif-
ference in the incidence of early deﬁnite ST (EDST) associated with the unrestricted
use of DES has not yet been documented. Therefore, the incidence of EDST in our
Japanese institute after unrestricted use of DES was retrospectively compared with
those reported in western mega-studies.
Methods and results: During the 40 months from August 2004 to November 2007
(before approval of clopidogrel in Japan), DES were implanted in 3605 lesions in 1885
patients in our institute; lesion- and patient-associated percentages of DES use were
95.2% and 94.7%, respectively. Mean stent length per lesion was 33.2mm, emergent
∗ Corresponding author. Tel.: +81 485 36 9900x2250; fax: +81 485 36 9920.
E-mail address: a2007135@pref.saitama.lg.jp (T. Ishikawa).
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Early deﬁnite stent thrombo
Conclusion: Due to differences in procedural approaches in Japan, the incidence of
EDST after unrestricted use of DES was signiﬁcantly lower than in western countries.
e of Cardiology. Published by Elsevier Ireland Ltd. All rights
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Peri-procedural anti-platelet therapy before
November 2007 was as previously reported
[2,9,10]. Ticlopidine (200mg) was immediately© 2009 Japanese Colleg
reserved.
ntroduction
evastating stent thrombosis (ST) associated with
he use of drug-eluting stents (DES) in Japanese
atients is known to be less frequent than in west-
rn countries [1,2]. Early deﬁnite stent thrombosis
EDST), according to the deﬁnition of the Academic
esearch Consortium (ARC) [3], which develops due
o several factors and has an incidence of approx-
mately half of the total deﬁnite ST within several
ears after the procedure [1,4—7], is also lower
n Japan than in western countries [1]. However,
n Japan, there has been a tendency to refrain
rom deploying DES in patients with ST-segment
levation myocardial infarction (STEMI) and acute
oronary syndrome (ACS), which are the major pre-
ictors for EDST [1,4—6,8]. Therefore, a statistical
omparison of the incidence of EDST after unre-
tricted use of DES in Japan to that in western
ountries has not yet been conducted.
In the present study, therefore, the incidence
f EDST after unrestricted use of DES [sirolimus-
luting stents (SES) or paclitaxel-eluting stents
PES)] including relatively high percentages of
TEMI patients in our Japanese institute over 40
onths with ticlopidine was retrospectively com-
ared with those reported in previous western
ega-studies [4—7] with clopidogrel.
ethods
opulation
his retrospective study was conducted by enrolling
ases of successful stent deployment during the 40
onths from August 2004 to November 2007 (i.e.
fter the approval of SES and until the approval of
lopidogrel). Not only elective but also emergent
ases of patients with ACS [composite of STEMI,
on-STEMI, and unstable angina pectoris (UAP)]
ere included. Doctors informed the patients of
g
p
t
1he safety and efﬁcacy of DES and obtained consent
see the ﬁrst paragraph of Discussion). At our insti-
ute [2,9,10], DES (SES or PES) was the ﬁrst choice,
ather than bare-metal stents (BMS), after approval
f SES was obtained. During the study period,
esion- and patient-associated percentages of DES
se were 95.2 and 94.7%, respectively, although
election of the stent type from among several
inds of BMS and DES (SES and PES) depended on
he doctor’s discretion, without randomization.
tent deployment
tents were implanted with visual angiographic
stimation and largely under the guidance of
ntravascular ultrasonography (IVUS-guide). Suc-
essful stent implantation was deﬁned as a
uccessful procedure without distinct angiographic
tent under-expansion [11]. When further stent
ilatation was needed, high-pressure ballooning
ith a non-compliant balloon [12] was usually
arried out. According to previous intravascular
ssessments [13,14], the minimal stent area tar-
et was at least 5.0—5.5mm2. For bifurcation
esion procedures, including the 2-stent technique,
se of ﬁnal kissing balloon (KBT) inﬂations was
ncouraged. For lesions that had the possibility
f developing slow- or no-reﬂow phenomenon,
articularly for ACS, use of a distal protection
ethod with the PercuSurge GuardWire® device
Medtronic, Santa Rosa, CA, USA) [15] was encour-
ged.
nti-platelet therapysis with DES in Japan 239
procedures and ST-elevation myocardial infarctions made up 33.7% and 16.4% of the
procedures, respectively, intravascular ultrasonography was used 96.0% of the time, a
distal protection device for acute coronary syndrome was used 68.7% of the time, and
the mean maximum inﬂation pressure was 19.5 atm. EDST was observed in ﬁve lesions
(0.139%) in four patients (0.212%). The incidence of patient-associated EDST at our
center was signiﬁcantly lower than in four western mega-studies (0.736%, 66 of 8970
patients; 0.634%, 149 of 23,500; 0.595%, 52 of 8402; 0.997%, 20 of 2006) (p < 0.05,
<0.01, <0.05, <0.01, respectively, using a 2-test).iven orally in emergent cases and, in cases of
lanned elective percutaneous coronary interven-
ion (PCI), ticlopidine (200mg/day) was prescribed
0—14 days previously. After a DES procedure,
240
Table 1 Baseline characteristics and lesion-
associated early deﬁnite stent thrombosis (EDST).
Continuous data are shown as mean values. IVUS:
intravascular ultrasonography; ACS: acute coronary
syndrome; STEMI: ST-elevation myocardial infarction;
LV: left ventricular; LAD: left anterior descending
artery; KBT: kissing balloon technique.
Total lesions (n) 3605
EDST (n, %) 5, 0.139
Stent number (/lesion) 1.38
Stent diameter (mm) 3.14
Stent length (mm) 33.2
Pressure (atm) 19.5
IVUS-guide (%) 96.0
Diabetes (%) 42.9
Chronic hemodialysis (%) 2.30
In-stent restenosis (%) 6.41
Emergent cases (%) 33.7
ACS (%) 33.2
ACS with distal protection (%/ACS) 68.7
STEMI (%) 16.4
LV dysfunction (%) 8.63
LAD (%) 40.1
Thrombus (%) 3.30
Calciﬁcation (%) 9.04
Bifurcation (%) 48.1
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different from that of PES.Bifurcation 2-stent (%/bifurcation) 13.1
KBT after bifurcation 2-stent (%) 96.5
ticlopidine was prescribed for at least 12 weeks,
and once recommended guidelines were available
[16], ticlopidine was prescribed for about 1 year;
however, these prescriptions were not prospec-
tively randomized. If adverse effects of ticlopidine
manifested, cilostazol was substituted as a second
choice (200—300mg/day). Furthermore, if adverse
effects of cilostazol were observed, clopidogrel
(75mg/day) was administered (the third choice,
see above) after informed consent and at the
doctor’s discretion. The precise incidence rate of
ticlopidine allergy was not known, as described in
Limitations, because ticlopidine allergy was not
prospectively deﬁned in terms such as the degree
of elevation of the serum level of enzymes due
to liver damage, etc. At our institute, clopidogrel
became available in September 2004 (as men-
tioned above), and eight patients were prescribed
it within 30 days after stenting.
Enrolled ST-related variables
EDST has been evaluated using multiple factors
[4—6,8,11,12,17—23], and the following variables
were estimated as baseline characteristics: stent
number [18] (number of implanted stents per
lesion), stent diameter [17] (maximum diameter
m
I
eT. Ishikawa et al.
f the balloon used to dilate the stent), stent
ength [4,18] (length of the stented segment, calcu-
ated by adding the length of each SES, regardless
f overlap), pressure [12,17] (maximum pressure
t maximum inﬂation diameter of the balloon),
VUS-guide [19,20] (availability of IVUS during PCI),
iabetes [4,6,17,21] (patients with diabetes mel-
itus), chronic hemodialysis [17,21] (patients with
hronic hemodialysis), in-stent restenosis [6,21]
lesion with in-stent restenosis in any type of stent),
mergent case [21] (lesions with stenting as part
f emergent procedures), ACS [4,8,21] (compos-
te of STEMI, NSTEMI, and UAP), ACS with distal
rotection [16] (ACS lesions treated with the dis-
al protection method), STEMI [4—6,17] (deﬁned
bove), left ventricular dysfunction [5] (left ven-
ricular ejection fraction less than 40% at PCI),
AD [4,19] (left anterior descending artery), throm-
us [22] (thrombus containing lesion), calciﬁcation
calciﬁed lesion, estimated using an angiogram and
VUS), bifurcation [5] (bifurcative lesions needing
ny treatment of the side branch), bifurcation 2-
tent [21] (bifurcation with application of a 2-stent
echnique), KBT after bifurcation 2-stent [23] (ﬁnal
BT performed after 2-stent technique).
tatistics
aseline characteristic variables are expressed only
s a mean value. Comparison of the rate of EDST to
our western mega-studies [4—7] was conducted as
2-test. A difference was considered signiﬁcant
hen the p-value was less than 0.05, using SPSS for
indows version 11.5 (SPSS Inc., Chicago, IL, USA).
esults
esion-associated ST-related variables
uring the 40 months after DES approval and before
lopidogrel approval in Japan (from August 2004 to
ovember 2007), DES was successfully deployed in
605 lesions in 1858 patients in our institute. As
hown in Table 1, the incidence of lesion-associated
DST after DES in our institute was 0.139% (5 of 3605
esions). The incidence of lesion-associated EDST
fter SES was 0.167% (5 of 3015 lesions) and that
f PES was 0% (0 of 590 lesions). The incidence of
esion-associated EDST of SES was not signiﬁcantlyMean stent length per lesion was 33.2mm. The
ean value of the pressure was 19.5 (atm), and
VUS-guide use was 96.0%. The percentages of
mergent and STEMI cases were 33.7% and 16.4%,
Early deﬁnite stent thrombosis with DES in Japan
Figure 1 Comparison of patient-driven early deﬁnite
stent thrombosis (EDST) after use of DES with EDST
reported in four western mega-studies. The incidence
of patient-associated EDST (0.212%, 4 of 1885 patients)
was signiﬁcantly lower than in four western mega-studies
reported by Pinto Slottow et al. [6] (0.595%, 52 of 8402),
Torre-Hernández et al. [4] (0.634%, 149 of 23,500), Stet-
tler et al. [7] (0.736%, 66 of 8970), and Ong et al. [5]
(0.997%, 20 of 2006) (p < 0.05, <0.01, <0.05, and <0.01,
r
n
E
r
6
l
1
b
2
C
a
T
4
f
t
e
(
o
t
D
T
o
t
E
d
s
w
T
c
t
d
p
‘
p
T
f
t
f
2
a
u
b
e
H
J
t
i
i
c
a
c
e
a
s
o
w
c
S
a
m
B
a
S
J
t
E
[
(
[
platelet aggregation, etc.) [32—35]. As the outcomeespectively, using a 2-test). Numerators and denomi-
ators in the graph express the numbers of patients with
DST and the entire cohort.
espectively. Use of a distal protection device was
8.7% among all cases of ACS. Among bifurcative
esions, the bifurcation 2-stent technique was used
3.1% of the time (sum of main branch and side
ranch), and KBT was used during the bifurcation
-stent procedure 96.5% of the time.
omparison of patient-associated EDST
fter use of DES with western mega-studies
he incidence of patient-associated EDST (0.212%,
of 1885 patients) was signiﬁcantly lower than in
our western mega-studies reported by Pinto Slot-
ow et al. [6] (0.595%, 52 of 8402), Torre-Hernández
t al. [4] (0.634%, 149 of 23,500), Stettler et al. [7]
0.736%, 66 of 8970), and Ong et al. [5] (0.997%, 20
f 2006) (p < 0.05, <0.01, <0.05, and <0.01, respec-
ively, using a 2-test) (Fig. 1).
iscussionhe major ﬁndings of the present study are that,
n the basis of a new deﬁnition of ST by ARC [3],
he incidences of lesion- and patient-associated
o
f
(
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DST after unrestricted use of DES with ticlopi-
ine in our Japanese institute were very low and
igniﬁcantly lower than those of western countries
ith clopidogrel mainly due to technical factors.
o our knowledge, this is the ﬁrst report indi-
ating a geographical and statistical difference in
he overall incidence of EDST, taking into account
ifferences in the ﬁrst-choice thienopyridine anti-
latelet agent other than aspirin.
‘Off-label’’ use of SES including for STEMI
atients
he rationale of unrestricted use of DES including
or STEMI patients has to be mentioned, because
he safety of unrestricted use of DES has not been
ully evaluated in Japanese patients. In August
004, when SES were approved in Japan, the safety
nd efﬁcacy of SES for STEMI [24] and unrestricted
tilization [25] were reported. Thus, SES could
e used in Japan based on the known safety and
fﬁcacy of off-label use of SES in daily practice.
owever, one of the major differences between
apan and western countries was in the use of
hienopyridine (ticlopidine and clopidogrel). Our
nstitute imported clopidogrel alone and prepared
t as a backup for ticlopidine and cilostazol. The
ontents of the informed consent were modiﬁed
nd approved by the committee of our prefecture
enter. Patients were informed of the safety and
fﬁcacy of SES reported from western countries
nd consent was obtained. After those reports, the
afety and efﬁcacy of SES for STEMI [26—28] and for
ff-label [28] use were consistently reported from
estern countries. Therefore, the authors did not
onsider SES unsuitable for off-label use including
TEMI and the authors reported [2,9,29] the safety
nd efﬁcacy of SES after unrestricted use and pri-
ary stenting for STEMI, although the efﬁcacy of
MS for STEMI in the DES era was reported [30] and
case of very late ST of DES was reported [31].
igniﬁcantly lower incidence of EDST in
apan than in western countries due to
echnical factors
DST has been evaluated using several factors
4—6,8,11,12,17—23], i.e. technical (procedural)
optimal stent dilation [11] etc.), patient (STEMI
4—6], etc.), and anti-platelet-related (potency off unrestricted use of DES, unfavorable factors
or EDST were included in the present cohort:
1) the mean total stent length [4,18] was long
approximately 33mm), (2) emergent procedures
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[21] and STEMI [4—6] were approximately one-third
and one-sixth of the cases, and (3) the percent-
age of bifurcation 2-stent procedures [21] was
approximately 6.3%. However, due to the following
technical (procedural) factors, EDST was consid-
ered to be rare in our institute. First, a very high use
of IVUS was advantageous for the reduction of EDST
in the DES era, because DES implantation under
the guidance of IVUS was the predictor of freedom
from ST [19,20]. Second, a high-pressure balloon-
ing [11,12] (almost the rated pressure) compared to
previous reports (the nominal pressure) [26] would
reduce the incidence of EDST. At a high-pressure
ballooning at stenting the culprit of ACS, distal
protection with PercuSurge GuardWire® device was
useful for obtaining a good post-procedural coro-
nary ﬂow [15], a predictor of EDST [17]. Thus, as
the third, but an indirect factor, a high use of distal
protection with PercuSurge GuardWire® device in
cases of ACS would contribute to lessening the inci-
dence of EDST. The rate of use of distal protection,
however, could not be compared with the recent
large-scale trial estimating EDST in ACS patients
[8]. Finally, high percentages of performing KBT as
part of the bifurcation 2-stent technique compared
to the previous randomized study (approximately
70%) [36] would contribute to the low incidence
of EDST. This was because bifurcation 2-stent tech-
nique was a predictor of EDST [21] and KBT with the
bifurcation 2-stent technique was a beneﬁcial pre-
dictor of MACE (major adverse cardiac events) [23].
Thus, by dilating stents optimally with these tech-
niques, the incidence of EDST after unrestricted use
of DES in our Japanese institute was signiﬁcantly
lower than that in western countries.
Involvement of differential thienopyridine
agent as the possible factor for difference in
EDST between Japan and western countries
In addition to these technical factors, the anti-
platelet therapy including the difference in
thienopyridine agent (i.e. ticlopidine in Japan vs.
clopidogrel in western countries) must be taken
into consideration. This was because the potency
of peri-procedural anti-platelet therapies was asso-
ciated with the occurrence of EDST [32—35] and
emergent cases made up approximately one-third
of the entire cohort (Table 1). EDST was signiﬁcantly
reduced under triple anti-platelet agents compared
to dual agents [32] and also with the use of pra-
sugrel compared to clopidogrel [33]. Regarding
clopidogrel, the insufﬁcient inhibition of platelet
aggregation that required assessment to alter the
dose [34] and the existence of pharmacodynamic
RT. Ishikawa et al.
on-responders ranging from 17% to 43% [37] were
eported. Therefore, the geographical difference
n thienopyridine usage might have affected the
eographical differences in EDST, although this was
nevitable because most data regarding ST in west-
rn countries were for studies using clopidogrel,
ut those in Japan were using ticlopidine. Thus, the
T incidence should be carefully evaluated for the
eriod after clopidogrel was substituted for ticlo-
idine as the ﬁrst-choice thienopyridine in Japan
after November 2007), and also, the incidence
f EDST after clopidogrel was approved in Japan
hould be compared with that in western countries.
n the other hand, the incidence of EDST would be
xpected to further decrease after the approvals
f prasugrel [33] and glycoprotein IIb/IIIa inhibitor
35] in Japan.
imitations
his retrospective, non-randomized, and single-
enter study has several limitations. The stent type
as not randomized. However, almost unrestricted
se of DES substantially increased the possibility of
eveloping EDST, as described above. The incidence
f EDST was compared based on the ﬁrst-choice
hienopyridine agents; therefore, the number of
atients with adverse effects related to ticlopi-
ine or clopidogrel that were substituted to other
nti-platelet therapies during the observational
nterval could not be clariﬁed. Although the unfa-
orable factors for EDST in our institute are noted
bove (Table 1), variables related to the patients,
argeted lesions, and procedures could not be sta-
istically compared with the previous four reports
4—7]. Factors related to quantitative coronary
ngiography and intravascular parameters associ-
ted with IVUS-related ST [38] were not estimated.
onclusions
efore the approval of clopidogrel, when ticlopi-
ine was the ﬁrst choice thienopyridine agent along
ith aspirin after DES implantation, EDST associ-
ted with unrestricted use of DES (SES and PES)
n our Japanese institute was rare and signiﬁcantly
ower than in western countries under clopidogrel
ue to technical factors.eferences
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